Back to search results

SBU-RESET: Relaxation, Stress Reduction and Epigenetics Trial in Cancer Survivors

This study, called SBU-RESET, is for cancer survivors who have completed their main cancer treatments. It's looking at whether mind-body practices like oncology-informed yoga or SMART (Stress Management and Resiliency Training) can improve your quality of life. Quality of life includes how you feel physically, socially, and emotionally. Researchers will also explore if these practices affect epigenetics, which is how your environment can influence your genes without changing your DNA. You could be eligible if you are over 18, have had lung cancer, colon cancer, or Non-Hodgkin's lymphoma, and finished cancer treatment at least six months ago. The study aims to enroll 100 participants.

Study design
This is a randomized interventional pilot study with 100 planned participants. It compares oncology-informed yoga to SMART (Stress Management and Resiliency Training).
What's involved
Participants will attend 8 weekly sessions of either oncology-informed yoga or SMART. Quality of life will be measured at 8 weeks.
Compensation
Not stated in the trial record.
Follow-up
Your quality of life will be measured at 8 weeks after starting the intervention.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT07161713

SBU-RESET: RElaxation, Stress Reduction and Epigenetics Trial in Cancer Survivors

Recruiting
NAAges 18+InterventionalSupportive care
Barbara Nemesure
~100 participants
Updated 2026-07-20 on ClinicalTrials.gov
What's tested:Oncology-informed yogaSMART

At a glance

Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Patient Reported Quality of Life (QOL) by EORTC QLQ-C30
Measured over 8 weeks
+25 more outcomes measured

Conditions

Cancer Survivors
Cancer Survivorship

Explore related trials

Colon CarcinomaHematologic NeoplasmLung CarcinomaNon-Hodgkin LymphomaSolid Neoplasm

Where it's being run

1 sites across 1 states
New York1

Study leadership

  • Barbara Nemesure, PhD · PRINCIPAL_INVESTIGATOR · Stony Brook University

Who to contact

Stony Brook Cancer Center Clinical Trials
[email protected]
631-728-7425
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Adults over 18 years old
Primary diagnosis: Lung Cancer, Colon Cancer and Non-Hodgkin's lymphoma (NHL)
Six months post cancer-directed treatment (chemotherapy, targeted and immunotherapy). Patients with active disease (e.g. metastatic colorectal cancer) who are not receiving any cancer-directed treatment are eligible.
Able to provide a saliva sample
Gives informed consent and agrees to be randomly assigned
Able to complete the questionnaire(s) in English.

Exclusion

Adults with primary anal and/or primary rectal cancer.
Adult cancer survivors who are currently on an active treatment regimen.
Oral or any pathological conditions that can limit the ability to produce saliva.
Unable to participate in full length study period and follow up thereafter.
Is pregnant or plan to become pregnant during the study period.
Currently practicing yoga or SMART
Those on corticosteroid therapy.
Documented fall or syncope within the last 6 months

What this trial measures

  • Patient Reported Quality of Life (QOL) by EORTC QLQ-C308 weeks

    Patient reported quality of life measured using the validated quality of life questionnaire C30 (QLQ-C30), developed by the European Organisation for Research and Treatment of Cancer. This scale includes 5 functional and 3 symptom scales, each scored as a 0-100 scale, where higher scores indicate a better outcome on functional scales and global health status, and a worse outcome on symptoms.

  • Patient Reported Quality of Life (QOL) by EORTC QLQ-SURV1008 weeks

    Patient-reported quality of life, measured using the EORTC QLQ-SURV100 a validated quality-of-life questionnaire developed by the European Organization for Research and Treatment of Cancer, evaluates survivorship-specific domains for QOL among disease-free survivors at least 1 year post-treatment, along with the validated EORTC disease-specific modules for the appropriate cancer type, and when applicable, 3 provisional site-specific survivorship modules. The SURV100 comprises 12 functional and 9 symptom scales, a symptom checklist, 4 single items, and 10 conditional items. Essentials survivorship scales consist of 73 items to evaluate short and long-term physical, psychological, and social domains unique to disease-free cancer survivors. Scores range from 0 to 100. A high score on a functional scale indicates a high/healthy level of functioning; a high score on the global health status/QL indicates a high QL, and a high score on a symptom item indicates a high level of symptomatology.

  • Patient Reported Quality of Life (QOL) by QLQ-ANL278 weeks

    Patient (anal carcinoma only) reported quality of life measured using questionnaire QLQ-ANL27, a validated 27-item health-related quality of life questionnaire developed by the European Organisation for Research and Treatment of Cancer (EORTC) for patients with anal carcinoma. It is used in conjunction with either the core EORTC QLQ-C30 or the core EORTC QLQ-SURV100 questionnaire, depending on disease status, to assess health-related quality of life, including aspects of symptom burden, physical condition, fatigue, emotional impact, and worries about health, which allows for better evaluation of treatments. An estimate of the average of the items in the scale is the raw score. The raw score is linearly transformed to a 0-100-point range with higher scores indicating a higher ("better") level of functioning or a higher ("worse") level of symptoms.

  • Patient Reported Quality of Life (QOL) by QLQ-BIL218 weeks

    Patient (cholangiocarcinoma and gallbladder cancer only) reported quality of life measured using questionnaire QLQ-BIL21, a validated 21-item health-related quality of life questionnaire developed by the European Organisation for Research and Treatment of Cancer (EORTC) for patients with cholangiocarcinoma and gallbladder cancer. It is used in conjunction with either the core EORTC QLQ-C30 or the core EORTC QLQ-SURV100 questionnaire, depending on disease status, to assess health-related quality of life, including aspects of symptom burden, physical condition, fatigue, emotional impact, and worries about health, which allows for better evaluation of treatments. An estimate of the average of the items in the scale is the raw score. The raw score is linearly transformed to a 0-100-point range with higher scores indicating a higher ("better") level of functioning or a higher ("worse") level of symptoms.

  • Patient Reported Quality of Life (QOL) by QLQ-BN208 weeks

    Patient (brain tumor only) reported quality of life measured using questionnaire QLQ-BN20, a validated 20-item health-related quality of life questionnaire developed by the European Organisation for Research and Treatment of Cancer (EORTC) for patients with brain tumors. It is used in conjunction with either the core EORTC QLQ-C30 or the core EORTC QLQ-SURV100 questionnaire, depending on disease status, to assess health-related quality of life, including aspects of symptom burden, physical condition, fatigue, emotional impact, and worries about health, which allows for better evaluation of treatments. An estimate of the average of the items in the scale is the raw score. The raw score is linearly transformed to a 0-100-point range with higher scores indicating a higher ("better") level of functioning or a higher ("worse") level of symptoms.

  • Patient Reported Quality of Life (QOL) by QLQ-BR428 weeks

    Patient (breast cancer only) reported quality of life measured using questionnaire QLQ-BR42, a validated 42-item health-related quality of life questionnaire developed by the European Organisation for Research and Treatment of Cancer (EORTC) for patients with breast cancer. It is used in conjunction with either the core EORTC QLQ-C30 or the core EORTC QLQ-SURV100 questionnaire, depending on disease status, to assess health-related quality of life, including aspects of symptom burden, physical condition, fatigue, emotional impact, and worries about health, which allows for better evaluation of treatments. An estimate of the average of the items in the scale is the raw score. The raw score is linearly transformed to a 0-100-point range with higher scores indicating a higher ("better") level of functioning or a higher ("worse") level of symptoms.

  • Patient Reported Quality of Life (QOL) by QLQ-CLL178 weeks

    Patient (chronic lymphocytic leukemia only) reported quality of life measured using questionnaire QLQ-CLL17, a validated 17-item health-related quality of life questionnaire developed by the European Organisation for Research and Treatment of Cancer (EORTC) for patients with chronic lymphocytic leukemia. It is used in conjunction with either the core EORTC QLQ-C30 or the core EORTC QLQ-SURV100 questionnaire, depending on disease status, to assess health-related quality of life, including aspects of symptom burden, physical condition, fatigue, emotional impact, and worries about health, which allows for better evaluation of treatments. An estimate of the average of the items in the scale is the raw score. The raw score is linearly transformed to a 0-100-point range with higher scores indicating a higher ("better") level of functioning or a higher ("worse") level of symptoms.

  • Patient Reported Quality of Life (QOL) by QLQ-CR298 weeks

    Patient (colorectal cancer only) reported quality of life measured using questionnaire QLQ-CR29, a validated 29-item health-related quality of life questionnaire developed by the European Organization for Research and Treatment of Cancer for patients with colorectal cancer. It is used in conjunction with either the core EORTC QLQ-C30 or the core EORTC QLQ-SURV100 questionnaire, depending on disease status, to assess health-related quality of life, including aspects of symptom burden, physical condition, fatigue, emotional impact, and worries about health, which allows for better evaluation of treatments. An estimate of the average of the items in the scale is the raw score. The raw score is linearly transformed to a 0-100-point range with higher scores indicating a higher ("better") level of functioning or a higher ("worse") level of symptoms.

  • Patient Reported Quality of Life (QOL) by QLQ-CX248 weeks

    Patient (cervical cancer only) reported quality of life measured using questionnaire QLQ-CX24, a validated 24-item health-related quality of life questionnaire developed by the European Organisation for Research and Treatment of Cancer (EORTC) for patients with cervical cancer. It is used in conjunction with either the core EORTC QLQ-C30 or the core EORTC QLQ-SURV100 questionnaire, depending on disease status, to assess health-related quality of life, including aspects of symptom burden, physical condition, fatigue, emotional impact, and worries about health, which allows for better evaluation of treatments. An estimate of the average of the items in the scale is the raw score. The raw score is linearly transformed to a 0-100-point range with higher scores indicating a higher ("better") level of functioning or a higher ("worse") level of symptoms

  • Patient Reported Quality of Life (QOL) by QLQ-EN248 weeks

    Patient (endometrial cancer only) reported quality of life measured using questionnaire QLQ-EN24, a validated 24-item health-related quality of life questionnaire developed by the European Organisation for Research and Treatment of Cancer (EORTC) for patients with endometrial cancer. It is used in conjunction with either the core EORTC QLQ-C30 or the core EORTC QLQ-SURV100 questionnaire, depending on disease status, to assess health-related quality of life, including aspects of symptom burden, physical condition, fatigue, emotional impact, and worries about health, which allows for better evaluation of treatments. An estimate of the average of the items in the scale is the raw score. The raw score is linearly transformed to a 0-100-point range with higher scores indicating a higher ("better") level of functioning or a higher ("worse") level of symptoms.

  • Patient Reported Quality of Life (QOL) by QLQ-GINET218 weeks

    Patient (neuroendocrine carcinoind only) reported quality of life measured using questionnaire QLQ-GINET21, a validated 21-item health-related quality of life questionnaire developed by the European Organisation for Research and Treatment of Cancer (EORTC) for patients with neuroendocrine carcinoid. It is used in conjunction with either the core EORTC QLQ-C30 or the core EORTC QLQ-SURV100 questionnaire, depending on disease status, to assess health-related quality of life, including aspects of symptom burden, physical condition, fatigue, emotional impact, and worries about health, which allows for better evaluation of treatments. An estimate of the average of the items in the scale is the raw score. The raw score is linearly transformed to a 0-100-point range with higher scores indicating a higher ("better") level of functioning or a higher ("worse") level of symptoms.

  • Patient Reported Quality of Life (QOL) by QLQ-HCC188 weeks

    Patient (hepatocellular carcinoma only) reported quality of life measured using questionnaire QLQ-HCC18, a validated 18-item health-related quality of life questionnaire developed by the European Organisation for Research and Treatment of Cancer (EORTC) for patients with hepatocellular carcinoma. It is used in conjunction with either the core EORTC QLQ-C30 or the core EORTC QLQ-SURV100 questionnaire, depending on disease status, to assess health-related quality of life, including aspects of symptom burden, physical condition, fatigue, emotional impact, and worries about health, which allows for better evaluation of treatments. An estimate of the average of the items in the scale is the raw score. The raw score is linearly transformed to a 0-100-point range with higher scores indicating a higher ("better") level of functioning or a higher ("worse") level of symptoms.

  • Patient Reported Quality of Life (QOL) by EORTC QLQ-HL278 weeks

    Patient (Hodgkin Lymphoma only) reported quality of life measured using questionnaire QLQ-HL27, a validated 27-item health-related quality of life questionnaire developed by the European Organisation for Research and Treatment of Cancer (EORTC) for patients with Hodgkin Lymphoma. It is used in conjunction with either the core EORTC QLQ-C30 or the core EORTC QLQ-SURV100 questionnaire, depending on disease status, to assess health-related quality of life, including aspects of symptom burden, physical condition, fatigue, emotional impact, and worries about health, which allows for better evaluation of treatments. An estimate of the average of the items in the scale is the raw score. The raw score is linearly transformed to a 0-100-point range with higher scores indicating a higher ("better") level of functioning or a higher ("worse") level of symptoms.

  • Patient Reported Quality of Life (QOL) by EORTC QLQ-HN438 weeks

    Patient (head \& neck cancer only) reported quality of life measured using questionnaire QLQ-HN43, a validated 43-item health-related quality of life questionnaire developed by the European Organisation for Research and Treatment of Cancer (EORTC) for patients with head \& neck cancer. It is used in conjunction with either the core EORTC QLQ-C30 or the core EORTC QLQ-SURV100 questionnaire, depending on disease status, to assess health-related quality of life, including aspects of symptom burden, physical condition, fatigue, emotional impact, and worries about health, which allows for better evaluation of treatments. An estimate of the average of the items in the scale is the raw score. The raw score is linearly transformed to a 0-100-point range with higher scores indicating a higher ("better") level of functioning or a higher ("worse") level of symptoms.

  • Patient Reported Quality of Life (QOL) by QLQ-LC298 weeks

    Patient (lung cancer only) reported quality of life measured using the questionnaire QLQ-LC29, a validated 29-item health-related quality of life questionnaire developed by the European Organisation for Research and Treatment of Cancer (EORTC) for patients with lung cancer. It is used in conjunction with either the core EORTC QLQ-C30 or the core EORTC QLQ-SURV100 questionnaire, depending on disease status, to assess health-related quality of life, including aspects of symptom burden, physical condition, fatigue, emotional impact, and worries about health, which allows for better evaluation of treatments. An estimate of the average of the items in the scale is the raw score. The raw score is linearly transformed to a 0-100-point range with higher scores indicating a higher ("better") level of functioning or a higher ("worse") level of symptoms.

  • Patient Reported Quality of Life (QOL) by EORTC QLQ-LMC218 weeks

    Patient (colorectal liver metastasis only) reported quality of life measured using questionnaire QLQ-LMC21, a validated 21-item health-related quality of life questionnaire developed by the European Organisation for Research and Treatment of Cancer (EORTC) for patients with colorectal liver metastasis. It is used in conjunction with the core EORTC QLQ-C30 questionnaire to assess health-related quality of life, including aspects of symptom burden, physical condition, fatigue, emotional impact, and worries about health, which allows for better evaluation of treatments. An estimate of the average of the items in the scale is the raw score. The raw score is linearly transformed to a 0-100-point range with higher scores indicating a higher ("better") level of functioning or a higher ("worse") level of symptoms.

  • Patient Reported Quality of Life (QOL) QLQ-MY208 weeks

    Patient (multiple myeloma only) reported quality of life measured using questionnaire QLQ-MY20, a validated 20-item health-related quality of life questionnaire developed by the European Organisation for Research and Treatment of Cancer (EORTC) for patients with multiple myeloma. It is used in conjunction with either the core EORTC QLQ-C30 or the core EORTC QLQ-SURV100 questionnaire, depending on disease status, to assess health-related quality of life, including aspects of symptom burden, physical condition, fatigue, emotional impact, and worries about health, which allows for better evaluation of treatments. An estimate of the average of the items in the scale is the raw score. The raw score is linearly transformed to a 0-100-point range with higher scores indicating a higher ("better") level of functioning or a higher ("worse") level of symptoms.

  • Patient Reported Quality of Life (QOL) by QLQ-NHL-HG298 weeks

    Patient (high-grade non-Hodgkin lymphoma cancer only) reported quality of life measured using the questionnaire QLQ-NHL-HG29, a validated 29-item health-related quality of life questionnaire developed by the European Organisation for Research and Treatment of Cancer (EORTC) for patients with high-grade non-Hodgkin lymphoma (HG-NHL). It is used in conjunction with either the core EORTC QLQ-C30 or the core EORTC QLQ-SURV100 questionnaire, depending on disease status, to assess health-related quality of life, including aspects of symptom burden, physical condition, fatigue, emotional impact, and worries about health, which allows for better evaluation of treatments. An estimate of the average of the items in the scale is the raw score. The raw score is linearly transformed to a 0-100-point range with higher scores indicating a higher ("better") level of functioning or a higher ("worse") level of symptoms.

  • Patient Reported Quality of Life (QOL) by QLQ-NHL-LG208 weeks

    Patient (low-grade non-Hodgkin lymphoma cancer only) reported quality of life measured using questionnaire QLQ-NHL-LG20, a validated 20-item health-related quality of life questionnaire developed by the European Organisation for Research and Treatment of Cancer (EORTC) for patients with low-grade non-Hodgkin lymphoma (LG-NHL). It is used in conjunction with either the core EORTC QLQ-C30 or the core EORTC QLQ-SURV100 questionnaire, depending on disease status, to assess health-related quality of life, including aspects of symptom burden, physical condition, fatigue, emotional impact, and worries about health, which allows for better evaluation of treatments. An estimate of the average of the items in the scale is the raw score. The raw score is linearly transformed to a 0-100-point range with higher scores indicating a higher ("better") level of functioning or a higher ("worse") level of symptoms.

  • Patient Reported Quality of Life (QOL) QLQ-OES188 weeks

    Patient (esophageal cancer only) reported quality of life measured using questionnaire QLQ-OES18 a validated 18-item health-related quality of life questionnaire developed by the European Organisation for Research and Treatment of Cancer (EORTC) for patients with esophageal cancer. It is used in conjunction with either the core EORTC QLQ-C30 or the core EORTC QLQ-SURV100 questionnaire, depending on disease status, to assess health-related quality of life, including aspects of symptom burden, physical condition, fatigue, emotional impact, and worries about health, which allows for better evaluation of treatments. An estimate of the average of the items in the scale is the raw score. The raw score is linearly transformed to a 0-100-point range with higher scores indicating a higher ("better") level of functioning or a higher ("worse") level of symptoms.

  • Patient Reported Quality of Life (QOL) QLQ-OG258 weeks

    Patient (esophago-gastric cancer only) reported quality of life measured using questionnaire QLQ-OG25, a validated 25-item health-related quality of life questionnaire developed by the European Organisation for Research and Treatment of Cancer (EORTC) for patients with esophago-gastric cancer. It is used in conjunction with either the core EORTC QLQ-C30 or the core EORTC QLQ-SURV100 questionnaire, depending on disease status, to assess health-related quality of life, including aspects of symptom burden, physical condition, fatigue, emotional impact, and worries about health, which allows for better evaluation of treatments. An estimate of the average of the items in the scale is the raw score. The raw score is linearly transformed to a 0-100-point range with higher scores indicating a higher ("better") level of functioning or a higher ("worse") level of symptoms.

  • Patient Reported Quality of Life (QOL) QLQ-OV288 weeks

    Patient (ovarian cancer only) reported quality of life measured using questionnaire QLQ-OV28, a validated 28-item health-related quality of life questionnaire developed by the European Organisation for Research and Treatment of Cancer (EORTC) for patients with ovarian cancer. It is used in conjunction with either the core EORTC QLQ-C30 or the core EORTC QLQ-SURV100 questionnaire, depending on disease status, to assess health-related quality of life, including aspects of symptom burden, physical condition, fatigue, emotional impact, and worries about health, which allows for better evaluation of treatments. An estimate of the average of the items in the scale is the raw score. The raw score is linearly transformed to a 0-100-point range with higher scores indicating a higher ("better") level of functioning or a higher ("worse") level of symptoms.

  • Patient Reported Quality of Life (QOL) QLQ-PR258 weeks

    Patient (prostate cancer only) reported quality of life measured using questionnaire QLQ-PR25, a validated 25-item health-related quality of life questionnaire developed by the European Organisation for Research and Treatment of Cancer (EORTC) for patients with prostate cancer. It is used in conjunction with either the core EORTC QLQ-C30 or the core EORTC QLQ-SURV100 questionnaire, depending on disease status, to assess health-related quality of life, including aspects of symptom burden, physical condition, fatigue, emotional impact, and worries about health, which allows for better evaluation of treatments. An estimate of the average of the items in the scale is the raw score. The raw score is linearly transformed to a 0-100-point range with higher scores indicating a higher ("better") level of functioning or a higher ("worse") level of symptoms.

  • Patient Reported Quality of Life (QOL) QLQ-STO228 weeks

    Patient (gastric cancer only) reported quality of life measured using questionnaire QLQ-STO22, a validated 22-item health-related quality of life questionnaire developed by the European Organisation for Research and Treatment of Cancer (EORTC) for patients with gastric cancer. It is used in conjunction with either the core EORTC QLQ-C30 or the core EORTC QLQ-SURV100 questionnaire, depending on disease status, to assess health-related quality of life, including aspects of symptom burden, physical condition, fatigue, emotional impact, and worries about health, which allows for better evaluation of treatments. An estimate of the average of the items in the scale is the raw score. The raw score is linearly transformed to a 0-100-point range with higher scores indicating a higher ("better") level of functioning or a higher ("worse") level of symptoms.

  • Patient Reported Quality of Life (QOL) QLQ-TC268 weeks

    Patient (testicular cancer only) reported quality of life measured using questionnaire QLQ-TC26, a validated 26-item health-related quality of life questionnaire developed by the European Organisation for Research and Treatment of Cancer (EORTC) for patients with testicular cancer. It is used in conjunction with either the core EORTC QLQ-C30 or the core EORTC QLQ-SURV100 questionnaire, depending on disease status, to assess health-related quality of life, including aspects of symptom burden, physical condition, fatigue, emotional impact, and worries about health, which allows for better evaluation of treatments. An estimate of the average of the items in the scale is the raw score. The raw score is linearly transformed to a 0-100-point range with higher scores indicating a higher ("better") level of functioning or a higher ("worse") level of symptoms.

  • Patient Reported Quality of Life (QOL) QLQ-THY348 weeks

    Patient (thyroid cancer only) reported quality of life measured using questionnaire QLQ-THY34, a validated 34-item health-related quality of life questionnaire developed by the European Organisation for Research and Treatment of Cancer (EORTC) for patients with thyroid cancer. It is used in conjunction with either the core EORTC QLQ-C30 or the core EORTC QLQ-SURV100 questionnaire, depending on disease status, to assess health-related quality of life, including aspects of symptom burden, physical condition, fatigue, emotional impact, and worries about health, which allows for better evaluation of treatments. An estimate of the average of the items in the scale is the raw score. The raw score is linearly transformed to a 0-100-point range with higher scores indicating a higher ("better") level of functioning or a higher ("worse") level of symptoms.